Galecto Biotech recently raised €79m in a Series C funding round. Chief medical officer Richard Marshall spoke to Scrip about how it plans to invest the capital in its pipeline treatment for idiopathic pulmonary fibrosis.
Danish firm Galecto Biotech AB is readying its inhaled treatment for idiopathic pulmonary fibrosis (IPF), TD139, a selective inhibitor of galectin-3, for international Phase II/III trials.
TD139 is a specific inhibitor of the galactoside binding pocket of galectin-3. It has been formulated for inhalation to enable...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
